A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
General Information Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 276M | 276M | 237M | 198M | 164M | 156M |
| Net Income | 17M | 17M | 10M | -3.2M | -17M | -7.5M |
| EPS | $0.32 | $0.32 | $0.20 | $-0.07 | $-0.35 | $-0.16 |
| Free Cash Flow | 25M | 25M | -5.8M | 15M | 10M | 21M |
| ROIC | 4.1% | 5.3% | 3.0% | -1.5% | -9.2% | -4.9% |
| Gross Margin | 74.4% | 74.4% | 72.6% | 68.6% | 66.8% | 67.9% |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 11M | 11M | 4.5M | -6.5M | -17M | -7.9M |
| Operating Margin | 4.0% | 4.0% | 1.9% | -3.3% | -10.4% | -5.0% |
| ROE | 4.7% | 5.1% | 4.0% | -1.5% | -9.2% | -4.9% |
| Shares Outstanding | 52M | 52M | 52M | 45M | 48M | 47M |
Vericel Corp passes 4 of 9 quality checks, suggesting mixed fundamentals.
Vericel Corp trades at 107.6x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 70.6x vs a median of 89.3x. The company's 5-year average gross margin is 70.1%. At current prices, the estimated annualized return to fair value is +9.8%.
Vericel Corp (VCEL) has a current P/E ratio of 107.6, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
Vericel Corp (VCEL) has a 5-year average return on invested capital (ROIC) of -1.5%. This is below average and may indicate limited pricing power.
Vericel Corp (VCEL) has a market capitalization of $1.8B. It is classified as a small-cap stock.
Vericel Corp (VCEL) does not currently pay a regular dividend.
Based on historical P/E analysis, Vericel Corp (VCEL) appears expensive. The current P/E of 107.6 is 617% above its historical median of 15.0. The estimated fair value CAGR (P/E method) is 156.5%.
Vericel Corp (VCEL) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Vericel Corp (VCEL) reported annual revenue of $276 million in its most recent fiscal year, based on SEC EDGAR filings.
Vericel Corp (VCEL) has a net profit margin of 6.0%. This is a modest margin.
Vericel Corp (VCEL) generated $25 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Vericel Corp (VCEL) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Vericel Corp (VCEL) reported earnings per share (EPS) of $0.32 in its most recent fiscal year.
Vericel Corp (VCEL) has a return on equity (ROE) of 5.1%. This indicates moderate shareholder returns.
Vericel Corp (VCEL) has a 5-year average gross margin of 70.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for Vericel Corp (VCEL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Vericel Corp (VCEL) has a book value per share of $6.87, based on its most recent annual SEC filing.
No recent press releases.